剖析阿托伐他汀联合曲美他嗪治疗冠心病临床疗效.docVIP

剖析阿托伐他汀联合曲美他嗪治疗冠心病临床疗效 　　【摘要】目的：分析阿托伐他汀联合曲美他嗪治疗冠心病临床疗效。方法：将本院2016年3月到2017年3月收治的86例冠心病患者视为分析对象，将其按照入院顺序纳入联合组与参照组（n=43）。联合组应用阿托伐他汀与曲美他嗪治疗，参照组仅应用曲美他嗪治疗，比较两组患者的临床治疗总有效率以及不良反应发生情况。结果：参照组患者临床治疗总有效率为83.72%，与联合组患者临床治疗总有效率97.67%对比具有明显区别（p0.05）。参照组患者不良反应发生率为11.63%，数据对比显著高于联合组患者不良反应发生率2.33%，组间差异比较具有统计学价值（p0.05）。结论：阿托伐他汀联合曲美他嗪治疗冠心病的临床疗效显著，临床治疗有效率与安全性比较理想，建议在冠心病患者治疗期间推广应用。 　　【关键词】阿托伐他汀；曲美他嗪；冠心病；临床治疗 　　[Abstract] Objective：To analyze the clinical efficacy of Atorvastatin Combined with trimetazidine in the treatment of coronary artery disease. Methods： 86 patients with coronary heart disease treated in our hospital from March 2016 to March 2017 were regarded as objects of analysis，and they were enrolled in the combined group and the reference group（n=43）according to the order of admission. The combined group was treated with atorvastatin and trimetazidine，and the reference group was treated with trimetazidine only. The total effective rate and adverse reactions of the two groups were compared. Results： the total effective rate of the patients in the reference group was 83.72%，which was significantly different from that of the combined group（P 0.05），and the total effective rate was 97.67%. The incidence of adverse reactions in the reference group was 11.63%，and the data was significantly higher than that in the combined group. The incidence of adverse reactions was 2.33%，and the difference between the two groups was statistically significant（P 0.05）. Conclusion： Atorvastatin Combined with trimetazidine in the treatment of coronary heart disease clinical curative effect is remarkable，the clinical treatment efficiency and safety is ideal，it is suggested that during the treatment of coronary heart disease patients to promote the application. 　　[Key words] atorvastatin；trimetazidine；coronary heart disease；clinical treatment 　　【中?D分类号】R541.4 【文献标识码】A 【文章编号】2095-6851（2017）06-00-01 　　冠心病具有慢性、进展性以及终身性的特点，作为常见的心血管疾病，临床用药的方式会直接影响到患者的临床治疗效果，对患者生命健康也会产生重要影响。文章将本院2016年3月到2017年3月收治的86例冠